



ANTIMICROBIAL SUSCEPTIBILITY PROFILE (01/01/2022 to 12/31/2022)
MedStar Montgomery Medical Center

 MedStar Montgomery Medical Center Gram Negative Organisms	Percent Susceptible																			
	Number of Isolates	Amikacin****	Amoxicillin-Clavulanate	Ampicillin	Ampicillin/sulbactam	Aztreonam	Cefazolin (Systemic ^a)	Cefazolin (Urine ^b)	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	ESBL (Negative)	Gentamicin****	Meropenem	Nitrofurantoin*	Piperacillin/tazobactam	Tetracycline	Tobramycin****	Trimethoprim/Sulfa
<i>Acinetobacter baumannii</i>	12**	100	-	-	42	-	-	60	-	-	-	-	-	-	-	-	-	-	83	-
<i>Enterobacter cloacae</i>	28	100	0	-	-	68	-	79	68	68	79	-	89	100	67	71	0	89	79	
<i>Escherichia coli</i>	560	100	0	47	-	79	38	44	82	79	79	61	80	88	100	98	94	0	86	66
<i>Klebsiella oxytoca</i>	19**	100	0	0	-	79	-	-	100	84	79	95	84	95	100	100	79	0	95	84
<i>Klebsiella pneumoniae ssp pneumoniae</i>	163	100	0	0	-	73	37	41	74	73	73	73	88	99	50	87	0	85	78	
<i>Proteus mirabilis</i>	51	96	0	67	-	96	0	74	96	86	90	75	-	90	-	0	98	0	90	67
<i>Pseudomonas aeruginosa</i>	101	100	0	0	-	76	-	-	89	89	0	75	-	-	87	0	81	0	99	0

 MedStar Montgomery Medical Center Gram Positive Organisms	Percent Susceptible											
	Number of Isolates	Ampicillin	Clindamycin	Daptomycin	Erythromycin	Linezolid	Moxifloxacin	Nitrofurantoin*	Oxacillin	Tetracycline	Trimethoprim/Sulfa	Vancomycin
<i>Enterococcus faecalis</i>	74	100	0	99	0	100	-	92	-	50	0	100
<i>Enterococcus faecium</i>	9**	67	0	100	0	100	-	0	-	40	0	68
Methicillin resistant <i>Staphylococcus aureus</i> (MRSA)***	79	0	53	97	9	100	-	100	0	79	84	100
Methicillin sensitive <i>Staphylococcus aureus</i> (MSSA)	94	0	83	100	61	100	-	100	100	90	82	100
<i>Staphylococcus coagulase-negative</i>	166	0	70	100	-	99	-	0	53	-	-	100

Percent Susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient

(-) Drug not tested or drug not indicated

(**) Data on the number of isolates less than 30 may not be statistically significant

(***) MRSA rate of the institution was 45% (****) Based on CLSI M100-32nd Ed breakpoints

^a Cefazolin (systemic), MIC ≤ 2 µg/mL susceptible for infections other than uncomplicated UTIs

^b Cefazolin (urine), MIC ≤ 16 µg/mL susceptible